# Curaleaf Holdings, Inc.: overview

CURLF · OTC · CIK 1756770 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/curlf.md) · [Financials](/companies/curlf/financials.md) · [Filings](/companies/curlf/filings.md) · [Insiders](/companies/curlf/insiders.md)

Latest reported revenue: [$340.1m](/filings/0001756770-26-000075.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001756770-26-000075).

## Last eight quarters

| Line item | Unit | period not labelled (2019-03-31) | period not labelled (2020-03-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [311](/filings/0001756770-26-000075.md) | not reported | [340](/filings/0001756770-26-000075.md) |
| Gross margin | % | not reported | not reported | not reported | [49.3%](/filings/0001756770-26-000075.md) | not reported | [50.0%](/filings/0001756770-26-000075.md) |
| Operating margin | % | not reported | not reported | not reported | [2.0%](/filings/0001756770-26-000075.md) | not reported | [1.2%](/filings/0001756770-26-000075.md) |
| Net margin | % | not reported | not reported | not reported | [(17.1%)](/filings/0001756770-26-000075.md) | not reported | [3.7%](/filings/0001756770-26-000075.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.26)](/filings/0001756770-26-000075.md) | not reported | [0.05](/filings/0001756770-26-000075.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL not reported.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,196](/filings/0001558370-23-007893.md) | [1,275](/filings/0001756770-24-000016.md) | [1,347](/filings/0001756770-25-000008.md) | [1,334](/filings/0001756770-26-000019.md) | [1,268](/filings/0001756770-26-000019.md) |
| Gross margin | % | [47.6%](/filings/0001558370-23-007893.md) | [49.1%](/filings/0001756770-24-000016.md) | [45.6%](/filings/0001756770-25-000008.md) | [48.0%](/filings/0001756770-26-000019.md) | [49.8%](/filings/0001756770-26-000019.md) |
| Operating margin | % | [4.9%](/filings/0001558370-23-007893.md) | [5.1%](/filings/0001756770-24-000016.md) | [3.2%](/filings/0001756770-25-000008.md) | [1.9%](/filings/0001756770-26-000019.md) | [2.0%](/filings/0001756770-26-000019.md) |
| Net margin | % | [(17.2%)](/filings/0001558370-23-007893.md) | [(29.0%)](/filings/0001756770-24-000016.md) | [(20.9%)](/filings/0001756770-25-000008.md) | [(16.1%)](/filings/0001756770-26-000019.md) | [(18.2%)](/filings/0001756770-26-000019.md) |
| Diluted EPS | $ per share | [(0.29)](/filings/0001558370-23-007893.md) | [(0.52)](/filings/0001756770-24-000016.md) | [(0.39)](/filings/0001756770-25-000008.md) | [(0.32)](/filings/0001756770-26-000019.md) | [(0.35)](/filings/0001756770-26-000019.md) |
| Free cash flow | $m | [(230)](/filings/0001558370-23-007893.md) | [(88.2)](/filings/0001756770-24-000016.md) | [9.8](/filings/0001756770-25-000008.md) | [71.2](/filings/0001756770-26-000019.md) | [74.3](/filings/0001756770-26-000019.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/curlf/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $134.3m | 12,420,961 |  | New +12,420,961 |
| [ALBERT D MASON INC](/funds/1169318.md) | 2026-06-30 | $270.3k | 25,009 |  | New +25,009 |
| [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $357 | 33 |  | New +33 |
| [Financial Gravity Companies, Inc.](/funds/1377167.md) | 2026-06-30 | $357 | 33 |  | Not compared |
| [Sterling Capital Management LLC](/funds/1329883.md) | 2026-06-30 | $346 | 32 |  | New +32 |

## Recent filings

[All 217 filings](/companies/curlf/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 20:22 ET | [8-K](/filings/0001756770-26-000130.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000130 |
| 2026-10-06 | 17:47 ET | [8-K](/filings/0001756770-26-000126.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000126 |
| 2026-10-06 | 12:37 ET | [8-K](/filings/0001104659-26-113907.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113907 |
| 2026-10-05 | 22:26 ET | [8-K](/filings/0001756770-26-000121.md) | 5.02 Departure or appointment of officers or directors | 0001756770-26-000121 |
| 2026-10-01 | 21:28 ET | [8-K](/filings/0001756770-26-000118.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001756770-26-000118 |
| 2026-10-01 | 21:27 ET | [8-K](/filings/0001756770-26-000117.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001756770-26-000117 |
| 2026-09-16 | 16:29 ET | [8-K](/filings/0001756770-26-000111.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000111 |
| 2026-09-15 | 19:56 ET | [8-K](/filings/0001756770-26-000106.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000106 |
| 2026-09-14 | 19:30 ET | [8-K](/filings/0001756770-26-000102.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000102 |
| 2026-09-08 | 21:08 ET | [8-K](/filings/0001756770-26-000095.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001756770-26-000095 |

## Latest annual report

[Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001756770-26-000019.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6e7f53c7-e6a6-4e88-ab81-23c7190f6b3b)

## About the filer

- CIK: 1756770
- Tickers: CURLF
- Exchange: OTC
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: A1
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.